Key statistics
As of last trade Coherus Oncology Inc (CHRS:NMQ) traded at 1.67, -36.35% below its 52-week high of 2.62, set on Jan 27, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.59 |
|---|---|
| High | 1.67 |
| Low | 1.57 |
| Bid | 1.66 |
| Offer | 1.67 |
| Previous close | 1.65 |
| Average volume | 1.26m |
|---|---|
| Shares outstanding | 149.47m |
| Free float | 123.99m |
| P/E (TTM) | -- |
| Market cap | 246.63m USD |
| EPS (TTM) | -1.62 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 17:51 GMT.
More ▼
- Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026
- Coherus Oncology to Participate in Upcoming Investor Conferences
- Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
- Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
- Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
- Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
- Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
- Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
- Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
More ▼
